All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
NEW YORK, Sept. 24, 2023 /PRNewswire/ --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) between March 17, 2022 and June 20, 2023, both dates inclusive (the "Class Period"), of the important September 29, 2023 lead plaintiff deadline.
Read more at prnewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| ALDX | 6.31 | -0.60 | -8.68% |
| Aldeyra Therapeu | |||
/A%20concept%20image%20showing%20binary%20code%20with%20the%20ERROR%20message_%20Image%20by%20Danich%20Marmai%20via%20Shutterstock_.jpg)
/Jen-Hsun%20Huan%20NVIDIA's%20Founder%2C%20President%20and%20CEO%20by%20jamesonwu1972%20via%20Shutterstock.jpg)
/Quantum%20Computing/Image%20by%20Funtap%20via%20Shutterstock.jpg)